Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.

  title={Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.},
  author={M. E. de Kok and Caroline Holm-Wigerup and Michael Hauptmann and Rob J.A.M Michalides and Olle St{\aa}l and Sabine Linn and G{\"o}ran Landberg},
  journal={Journal of the National Cancer Institute},
  volume={101 24},
Although estrogen receptor-alpha (ER) [corrected] is a marker used to identify breast cancer patients most likely to benefit from endocrine therapy, approximately 50% of ER-positive [corrected] breast carcinomas are resistant to tamoxifen. Preclinical studies have shown that phosphorylation of ER [corrected] at serine-118 (ER alpha S118-P) is required for tamoxifen-mediated inhibition of ER-induced [corrected] gene expression. We evaluated the association between recurrence-free survival after… CONTINUE READING
21 Citations
21 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 21 extracted citations


Publications referenced by this paper.
Showing 1-10 of 21 references

Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer

  • C Holm, S Rayala, K Jirstrom, O Stal, R Kumar, G Landberg
  • J Pathol
  • 2008

Phospho - rylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen - resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression

  • J Jiang, N Sarwar, D Peston
  • Endocr Relat Cancer
  • 2006

Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D 1 gene amplifi cation

  • L Ryden, PE Jonsson, G Chebil
  • Cancer Res
  • 2005

Similar Papers

Loading similar papers…